<!doctype html>																																																																																										<head><title>CG-SURG-91 Minimally Invasive Ablative Procedures for Epilepsy</title><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="xUDType" content="Medical_Guideline"><meta name="file" content=""><meta name="UDCategory" content="SURG"><meta name="UDReference" content="CG-SURG-91"><meta name="UDType" content="Medical_Guideline"><meta name="UDStatus" content="Current"> <meta name="mpStatus" content="Revised"><meta name="title" content="CG-SURG-91"><meta name="xSortDate1" content="01/03/2024"><meta name="xSortPubTS" content="1704326399000"><meta name="date" content="01/03/2024"><link href="../../../css/cgmaster.css" rel="styleSheet" type="text/css" /><link href="../../../css/cgcommercial.css" rel="styleSheet" type="text/css" /> <script src="../../../js/adobeanalytics.js"></script>
<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"false","rua.uprl":"false","rua.cprl":"false","rua.cprf":"false","rua.trans":"","rua.cook":"false","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"false","rua.isuxp":"false","rua.texp":"norulematch"}]);</script>
                              <script>!function(a){var e="https://s.go-mpulse.net/boomerang/",t="addEventListener";if("True"=="True")a.BOOMR_config=a.BOOMR_config||{},a.BOOMR_config.PageParams=a.BOOMR_config.PageParams||{},a.BOOMR_config.PageParams.pci=!0,e="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="YDDHU-FFACC-3AYXK-XQKBX-62T4Z",function(){function n(e){a.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!a.BOOMR||!a.BOOMR.version&&!a.BOOMR.snippetExecuted){a.BOOMR=a.BOOMR||{},a.BOOMR.snippetExecuted=!0;var i,_,o,r=document.createElement("iframe");if(a[t])a[t]("load",n,!1);else if(a.attachEvent)a.attachEvent("onload",n);r.src="javascript:void(0)",r.title="",r.role="presentation",(r.frameElement||r).style.cssText="width:0;height:0;border:0;display:none;",o=document.getElementsByTagName("script")[0],o.parentNode.insertBefore(r,o);try{_=r.contentWindow.document}catch(O){i=document.domain,r.src="javascript:var d=document.open();d.domain='"+i+"';void(0);",_=r.contentWindow.document}_.open()._l=function(){var a=this.createElement("script");if(i)this.domain=i;a.id="boomr-if-as",a.src=e+"YDDHU-FFACC-3AYXK-XQKBX-62T4Z",BOOMR_lstart=(new Date).getTime(),this.body.appendChild(a)},_.write("<bo"+'dy onload="document._l();">'),_.close()}}(),"".length>0)if(a&&"performance"in a&&a.performance&&"function"==typeof a.performance.setResourceTimingBufferSize)a.performance.setResourceTimingBufferSize();!function(){if(BOOMR=a.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var e=""=="true"?1:0,t="",n="wzdhuyixgvbdiztzidaa-f-e7395f605-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,_={"ak.v":"37","ak.cp":"202149","ak.ai":parseInt("244874",10),"ak.ol":"0","ak.cr":40,"ak.ipv":4,"ak.proto":"http/1.1","ak.rid":"1552dc27","ak.r":36095,"ak.a2":e,"ak.m":"a","ak.n":"essl","ak.bpcip":"182.70.122.0","ak.cport":52332,"ak.gh":"23.210.93.68","ak.quicv":"","ak.tlsv":"tls1.3","ak.0rtt":"","ak.csrc":"-","ak.acc":"reno","ak.t":"1719222464","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==pVjAwHhOZMw/skjUHDnduUG/3rdJbTdtRWL6vnKwOFRUwQ+b5R6RBxvPzIYjQMCP6CuzF5CnjOvgUiXnfQLX3D9uK6DVop0O4dcSnN8L39hPZ20ahaN0gYD2bcdpUSc55OFGezY7wWjvjyIpC9t9tQMcJwWOv1Pj0HyxjeelCY13zAZkoGaQ/wRp/dQAAEURWcbEpxpZy/mMsZU9Q82ujn6GEa+3nI+mHjwX3itewGl7JiMxRDHiwoQI6uqAfK2wIoNrBzKgLNkljoUTNma+ZwyiYaCRdTjclAuw7wQ/3ZJfYAd8lrhkY1qimXylQPrbmjz9WIWCnvvX/zFdYEvQC81b4+sTqUKJALpSGMaEn3KRNgMntnBlcCwBIof+WD0TAcahHatEGEmMgaC1NKOywNc2+ax/eEHyuLuYaXiMIWo=","ak.pv":"490","ak.dpoabenc":"","ak.tf":i};if(""!==t)_["ak.ruds"]=t;var o={i:!1,av:function(e){var t="http.initiator";if(e&&(!e[t]||"spa_hard"===e[t]))_["ak.feo"]=void 0!==a.aFeoApplied?1:0,BOOMR.addVar(_)},rv:function(){var a=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(a)}};BOOMR.plugins.AK={akVars:_,akDNSPreFetchDomain:n,init:function(){if(!o.i){var a=BOOMR.subscribe;a("before_beacon",o.av,null,null),a("onbeacon",o.rv,null,null),o.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><script >bazadebezolkohpepadr="1885181968"</script><script type="text/javascript" src="https://www.anthem.com/akam/13/705d9972"  defer></script></head><body><table> <tbody> <tr> <td><img class="logo_abc" src="../../images/abc.svg" /></td> <td id="policyTypeHeading">Clinical UM Guideline</td> </tr> </tbody> </table> <table id="docDetails"> <tbody> <tr> <td colspan="2"><strong>Subject:</strong> Minimally Invasive Ablative Procedures for Epilepsy</td> </tr> <tr> <td width="75%"><strong>Guideline #:</strong> CG-SURG-91</td> <td><strong>Publish Date:</strong> 01/03/2024</td> </tr> <tr> <td width="75%"><strong>Status:</strong> Revised</td> <td><strong>Last Review Date:</strong> 11/09/2023</td> </tr> </tbody> </table>  <table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Description</strong></td>		</tr>	</tbody></table><p>This document addresses minimally invasive ablative procedures used in the treatment of medically refractory epilepsy in individuals with symptomatic localized epilepsy. Minimally invasive procedures have been proposed as a means to minimize or eliminate major craniotomy and bone flap incisions, decrease pain and down-time, preserve tissue and decrease neurocognitive adverse effects. These procedures utilize laser, radiofrequency, or cryotherapy techniques, in combination with stereotactic magnetic resonance imaging (MRI) guidance, for targeted ablation of the epileptogenic foci.</p><p><strong>Note:</strong> This document does not address minimally invasive surgery to treat conditions other than epilepsy, including treatment of cancerous lesions.</p><ul>	<li><a href="../../../abc/active/guidelines/gl_pw_a050137.html"> CG-ANC-03 Acupuncture</a></li>	<li><a href="../../../abc/active/guidelines/gl_pw_a053724.html"> CG-MED-05 Ketogenic Diet for Treatment of Intractable Seizures</a></li>	<li><a href="../../../abc/active/policies/mp_pw_a050053.html"> MED.00057 MRI Guided High Intensity Focused Ultrasound Ablation for Non-Oncologic Indications</a></li>	<li><a href="../../../abc/active/policies/mp_pw_a050253.html"> SURG.00026 Deep Brain, Cortical, and Cerebellar Stimulation</a></li>	<li><a href="../../../abc/active/guidelines/gl_pw_d056821.html"> CG-SURG-61 Cryosurgical, Radiofrequency, Microwave or Laser Ablation to Treat Solid Tumors Outside the Liver</a></li></ul><table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Clinical Indications</strong></td>		</tr>	</tbody></table><p><strong>Medically</strong><strong> Necessary:</strong></p><p>The treatment of medically refractory epilepsy using stereotactic laser techniques (MRI-guided laser interstitial thermal ablation [MRIgLITT]), including stereotactic laser amygdalohippocampotomy (SLAH), is considered <strong>medically necessary </strong>when both of the following criteria are met:</p><ol start="1" style="list-style-type:upper-alpha">	<li>Documented disabling seizures despite the use of two or more tolerated antiepileptic drug regimens; <strong>and</strong></li>	<li>Documented presence of two or fewer well delineated epileptogenic foci accessible by laser.</li></ol><p>The use of stereotactic radiofrequency thermocoagulation (RF-TC) in the treatment of hypothalamic hamartomas is considered <strong>medically necessary.</strong></p><p><strong>Not Medically Necessary:</strong></p><p>The treatment of medically refractory epilepsy using stereotactic laser techniques or stereotactic radiofrequency thermocoagulation is considered <strong>not medically necessary</strong> when the criteria above have not been met.</p><p>Other minimally invasive procedures to treat medically intractable epilepsy are considered <strong>not medically necessary,</strong> including but not limited to stereotactic radiofrequency amygdalohippocampectomy, sEEG-guided radiofrequency thermocoagulation or stereotactic cryosurgery.</p><table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Coding</strong></td>		</tr>	</tbody></table><p><em>The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member&#39;s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.</em></p><p><strong>When services may be Medically Necessary when criteria are met:</strong></p><table cellspacing="0" class="Table" style="border-collapse:collapse; margin-left:15px; width:682px">	<tbody>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p style="text-align:justify"><strong>CPT</strong></p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>&nbsp;</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p style="text-align:justify">64999</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Unlisted procedure, nervous system [when specified as minimally invasive surgery such as MRI-guided laser interstitial thermal ablation, radiofrequency thermal coagulation]</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p style="text-align:justify">&nbsp;</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>&nbsp;</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p><strong>ICD-10-Procedure</strong></p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>&nbsp;</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>00503Z3</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Destruction of brain using laser interstitial thermal therapy, percutaneous approach</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>&nbsp;</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>&nbsp;</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p><strong>ICD-10 Diagnosis</strong></p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>&nbsp;</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>D33.0</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Benign neoplasm of brain, supratentorial [specified as hypothalamic hamartoma]</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:137px">			<p>G40.001-G40.919</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:545px">			<p>Epilepsy and recurrent seizures</p>			</td>		</tr>	</tbody></table><p style="text-align:justify"><strong>When services are Not Medically Necessary:</strong><br />For the procedure and diagnosis codes listed above when criteria are not met, or when the code describes a procedure designated in the Clinical Indications section as not medically necessary.</p><table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Discussion/General Information</strong></td>		</tr>	</tbody></table><p>Approximately 1.2% of the U.S population, or 3.4 million individuals have active epilepsy (CDC, 2023; Xue, 2018). Active epilepsy is defined as being physician diagnosed and having had one or more seizures in the past year or taking medication to control it, or both (CDC, 2023). Mesial temporal lobe epilepsy is a common type of epilepsy, representing approximately one-quarter of all cases; one-third of these individuals are considered medication refractory (Gross, 2018). Other types of epilepsy have varying degrees of success with pharmacotherapy. The failure of two anti-seizure medications (antiepileptic drugs [AEDs]) is approximately 97% reliable in identifying drug resistance (Kwan, 2010). The International League against Epilepsy defines drug resistant epilepsy as:</p><p style="margin-left:40px; margin-right:48px">failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom (Kwan, 2010).</p><p>While pharmacotherapy is the first line of treatment to control seizures, it does not effect complete seizure control in one-third of the individuals (LaRiviere, 2016). For this population, open procedures have been the gold standard in achieving lasting seizure control. These procedures, such as anterior temporal lobectomy (ATL) or selective amygdalohippocampotomy (SAH) involve localizing and excising the epileptogenic zones (Shukla, 2017). These open procedures typically report a 60-80% long-term seizure-free rate with 95% of individuals reporting an improvement (Chang, 2015; Kang, 2016). However, concerns about the invasiveness of the procedure and the effect on neuropsychological function have limited the number of individuals utilizing this option. Approximately 2% of those individuals considered candidates undergo open surgery every year (Kang, 2016). Neuromodulatory device implantation has also been used as a means of seizure frequency reduction and in those who undergo constant stimulation, the success rate is approximately 68-76% (Xue, 2018). Minimally invasive therapies have been explored as alternatives to open surgery. These therapies are proposed to be viable options for those with epileptogenic foci located near deep, eloquently situated brain structures, multiple comorbidities or those who are poor surgical candidates (Shukla, 2017).</p><p>Stereotactic LITT, typically MRI- guided, uses low-voltage laser energy delivered via optical fiber through a burr hole to destroy the targeted tissue while minimizing injury to the surrounding tissue. MRI-guided laser interstitial thermal therapy (MRgLITT) consists of three elements, stereotactic techniques to exactly position the laser in the therapeutic range, the use of the laser to provide time-dependent thermal tissue ablation and MRI thermography to provide real-time monitoring of temperature and tissue destruction (Dorfer, 2020). Laser energy is converted to thermal energy, which, when applied to tissue leads to coagulative necrosis. Use with MRI guidance allows for monitoring of both the device tip and thermal damage in real time (Gross, 2016; Shukla, 2017). However, LITT is not without drawbacks. Ablative therapies do not allow for tissue to be obtained for pathology, and Kang (2016) noted a technical limitation &ldquo;The curvature of the hippocampus and the presence of potential heat sinks (i.e., blood and cerebral spinal fluid) may prevent adequate ablation of the epileptogenic network in some individuals.&rdquo;</p><p><em>Laser interstitial therapy</em></p><p>There are two Food and Drug Administration (FDA) cleared MRgLITT systems, Visualase<sup>&reg;</sup> thermal therapy (Medtronic, MN) and NeuroBlate<sup>&reg;</sup> Systems (Monteris Medical, Minneapolis, MN). The Visualase device, approved in 2007, has been used to treat epilepsy since 2012 (Kang, 2016). The NeuroBlate device, approved in 2009, is not commonly used to treat epilepsy, but is typically used to treat brain tumors. The use of NeuroBlate to treat epilepsy is undergoing an FDA approved trial.</p><p>In 2022, the American Society for Stereotactic and Functional Neurosurgery (ASSFN) published a position statement on laser interstitial thermal therapy for the treatment of drug-resistant epilepsy (DRE). ASSFN acts as the joint section representing the field of stereotactic and functional neurosurgery on behalf of the Congress of Neurological Surgeons and the American Association of Neurological Surgeons. ASSFN concluded that the safety and efficacy of MRgLITT in reducing seizure frequency in patients with DRE has been demonstrated in several large peer-reviewed case series and are comparable with results reported from case series of open surgical procedures. ASSFN developed the following recommendations:</p><p style="margin-left:40px">Indications for the use of MRgLITT as a treatment option for patients with DRE include all of the following criteria:</p><ol>	<li>Failure to respond to, or intolerance of, at least 2 appropriately chosen medications at appropriate doses for disabling and localization-related epilepsy AND</li>	<li>Well-defined epileptogenic foci or critical pathways of seizure propagation accessible by MRgLITT.</li></ol><p>Contraindications include an inability to identify the epileptogenic focus, inability to undergo MRI because of medical reasons, or medical contraindications to surgery such as unstable cardiac or respiratory conditions or bleeding diatheses.</p><p>Chen and colleagues (2023) conducted a systematic review and meta-analysis to identify independent predictors of seizure outcome following MRgLITT for DRE. A total of 46 studies reporting on 450 individuals with DRE treated with MRgLITT were included. Overall, 57.8% of treated individuals were seizure-free at last follow-up. Cerebral cavernous malformation (CCM) and mesial temporal sclerosis/atrophy (MTS/A) were independently associated with greater odds of seizure freedom. MRgLITT was particularly effective in treating individuals with well-circumscribed lesional DRE, such as CCM, MTS/A and hypothalamic hamartomas, but less effective in nonlesional cases or lesional cases with a more diffuse epileptogenic network associated with generalized seizures.</p><p>In 2021, Barot and colleagues published a meta-analysis evaluating the effectiveness of MRgLITT in DRE. In total, 28 studies were identified which included 559 individuals with treatment-resistant epilepsy. Their primary outcome of interest was seizure freedom, which is typically reported by the Engel classification with at least 6 months of follow-up. Their secondary outcomes of interest were postoperative complications and reoperation rates. The overall prevalence of Engel class I outcome (free from disabling seizures) was 56%. Individuals with hypothalamic hamartomas had the highest seizure freedom rate (67%). The outcome was overall comparable between individuals with mesial temporal lobe epilepsy (mTLE, 56%) and extratemporal epilepsy (50%). The mTLE cases with mesial temporal sclerosis had better outcome compared with non-lesional cases of mTLE. A total of 25 studies, which included 519 individuals, reported postoperative adverse events. The prevalence of postoperative adverse events was 19% with the most common adverse event being visual field deficits which were most commonly noted in individuals with mTLE. Other relevant adverse events included intracranial hemorrhage (n=13) and motor deficits (n=27). The reoperation rate was 9% in only 18 of 28 studies with reported data. Reoperative events included repeated ablation (n=55) and resective surgery (n=18). Their review indicates that MRgLITT can be an effective and safe therapy for DRE. However, a majority of the evidence is limited to retrospective studies with diverse etiologies of DRE.</p><p>In 2021, Kohlhase and colleagues published a meta-analysis to compare the outcomes and complications between MRgLITT, radiofrequency ablation (RFA), and conventional surgical approaches to the temporal lobe (such as, ATL or selective amygdalohippocampectomy [sAHE]) for the treatment of drug-refractory mTLE. A total of 43 studies (13 MRgLITT, 6 RFA, and 24 surgery studies) involving 554, 123, 1504, and 1326 individuals treated by MRgLITT, RFA, ATL, or sAHE, respectively, were included in the analysis. Engel class I outcomes were achieved after MRgLITT in 57%, RFA in 44%, ATL in 69%, and sAHE in 66% of participants. There was no significant difference in seizure outcome between MRgLITT and RFA (p=0.098). The authors report that compared with MRgLITT, participants that received ATL (p=0.002) or sAHE (p=0.037) had significantly better outcomes, with better outcomes at follow-up of 60 months or more. Similarly, participants who received ATL (p=0.113) and sAHE (p=0.0247) compared to RFA had significantly better outcomes. However, the authors note a large difference in the range of follow-up periods between the surgical groups (12 to 116.4 months) and the MRgLITT (6 to 70 months) and RFA (12 to 62 months) groups. Comparable long-term data for MRgLITT and RFA is not yet available. In a subgroup analysis for participants with follow-up less than 60 months, the difference in seizure outcomes was nonsignificant between MRgLITT and ATL (p=0.057) or sAHE (p=0.28). Mesial hippocampal sclerosis was associated with significantly better outcome after MRgLITT (Engel class I outcome in 64%, p=0.0035). The rate of major complications was lower for MRgLITT (3.8%) and RFA (3.7%) compared to ATL (10.9%) and sAHE (7.4%). However, the differences did not show statistical significance. Regarding neuropsychological deficits, lateral functions such as naming or object recognition may be more preserved in MRgLITT. Some of the limitations of the analysis include the retrospective uncontrolled design as well as lack of long-term follow-up of available MRgLITT and RFA studies.</p><p>In 2020, Wang and colleagues published a meta-analysis assessing the safety and effectiveness of MRgLITT and stereoelectroencephalography-guided radiofrequency thermocoagulation (SEEG-guided RF-TC) in treating DRE. A total of 26 studies were identified which included 804 participants. The minimum follow-up period was 6 months. The authors reported that those treated with MRgLITT had a significantly (p=0.00) greater overall rate of freedom from seizures (65%) compared to SEEG-guided RF-TC (23%). The analysis included those who received repeated ablations and became seizure free into the seizure-free group. The overall complication rate of 5% across all approaches was considered low in the two approaches. The authors proposed that the underlying mechanism of the highly different postoperative rates of seizure-free outcomes between MRgLITT and SEEG-guided RF-TC was most likely related to the sizes of the ablated lesions.</p><p>In 2020, Kerezoudis and colleagues published a systematic review with meta-analysis examining the effect of ablation volume on seizure freedom rate for individuals who received MRgLITT for TLE. A total of 13 studies including 551 participants were analyzed. The seizure freedom rate at the last follow-up was 58% for the entire cohort. The overall reported complication rate was 17% with a permanent complication rate of 5%. In the overall cohort, seizure freedom was not significantly associated with total ablation volume (p=0.42). The review was limited by the retrospective design, size, and lack of long-term follow-up of the included studies.</p><p>In 2018, Xue and colleagues conducted a meta-analysis of MRgLITT to assess effectiveness in treatment-resistant epilepsy. In total, 16 studies were identified which included 269 individuals with medication-resistant epilepsy with focal onset of seizures. In the short-term, 61% of the individuals were seizure-free or disabling seizure-free (Engel Class I) following MRgLITT. While approximately 24% of the individuals reported postoperative complications, the authors note that some complications resolve within 6 months. The authors note that while MRgLITT can achieve good outcomes, there are several factors which affect the effectiveness in the clinical setting. Good clinical outcomes depend upon accurate and precise localization of the epileptogenic zone. Inadequate resection of the epileptogenic focus, wider epileptogenic zones and inadequate training can result in suboptimal results.</p><p>Gross and colleagues (2018) evaluated outcomes of 58 individuals with mTLE with or without mesial temporal sclerosis who had undergone stereotactic laser amygdalohippocampotomy (SLAH). Analysis was limited to those with documented outcomes of 1 year or longer. For those for whom the initial SLAH procedure was ineffective, a repeat SLAH procedure was offered when the postoperative MRI scan showed a remnant region thought to be responsible for the ongoing procedures. Following SLAH, 53.4% (31/58) were considered free from disabling seizures, and 22 of the individuals achieved Engel 1A response at 12 months or longer, including 3 individuals who had undergone a repeat SLAH. An additional 9 individuals achieved Engel 1B-D responses. During the same period 22 individuals underwent open temporal lobe resections, with 50% (11/22) of these individuals considered seizure free at 1 year. Complications of SLAH include visual field defects in 5 individuals, with 1 being persistent and symptomatic. Other complications were transient and treated with resolution of symptoms. The authors reported that 8.2% of the individuals experienced decline in verbal memory, compared to rates of 30 to 60% decline reported for open resection. The authors note:</p><p style="margin-left:40px; margin-right:48px">Thus, on balance, although SLAH may yield a marginal decrease in the chance of freedom from disabling seizures, and possibly in the rate of being completely seizure-free, as compared to open resection, the cognitive benefits and safety profile of SLAH make it an attractive alternative, especially when considering surgery on the dominant hemisphere.</p><p>The outcomes of LITT to treat 43 consecutive individuals with mTLE who underwent unilateral therapy was reported by Donos and associates (2018). In addition to seizure free rates, cognitive function was assessed prior to and following the procedure, although 8 individuals did not return for follow-up testing. At 6 months following their procedure, 79.5% of the individuals had achieved an Engel class I outcome. An additional 5.1% achieved Engel class II and 15.4% were classified as having an Engel III outcome. In later follow-up (mean interval of 20.3 months), 67.4% of the individuals achieved an Engel class I outcome and an additional 16.3% of the individuals each achieved Engel class II and III. There were declines in some aspects of memory following the surgery, but changes observed at the group level were small and did not reach the level of significance. The authors noted that the follow-up testing was performed at 6 months, and as functional recovery continued, a further improvement in cognitive performance was likely to occur. The results of the study were similar to those of previous studies, the authors reported slightly higher rates of Engel I outcomes.</p><p>Kang and associates (2016) described the outcomes of 20 individuals with medically intractable mTLE who underwent MRgLITT between 2011 and 2014. Assessed outcomes included mesial temporal lobe ablated volumes, verbal memory, and surgical outcomes at 6 months, 1 year, 2 years and most recent visit. At 6 months, 8/15 individuals (53%; 95% confidence interval [CI], 30.1-75.2%) were free of consciousness impairing seizures. At 1 and 2 years, 4/11 individuals (36.4%; 95% CI, 14.9-64.8%) and 3/5 individuals (60%; 95% CI, 22.9-88.4%) were free of consciousness impairing seizures respectively. None of the participants reported a statistically reliable decline in logical memory performance. Reported efficacy rates are modestly lower than those reported after anterior temporal lobectomy (ATL). However, verbal learning and memory performance was better preserved in the MRgLITT group compared to the ATL group. In addition, the hospital stay postoperative pain and recovery period was minimal, and individuals were immediately able to return to work. The authors note that this finding might be significant for those with dominant mesial temporal foci, as individuals who undergo ATL in the dominant hemisphere are at higher risk for declines in language function and verbal memory.</p><p>In 2015, Waseem and colleagues reported on the outcomes of 7 individuals over the age of 50 who underwent MRgLITT for medically refractory mTLE. The outcomes were compared to 7 individuals who had undergone selective anterior mesial temporal lobe (AMTL) resection. All 7 individuals in the AMTL group were seizure free at 12 months. In the MRgLITT group, 4 individuals were classified as seizure free, 1 individual reported rare seizures (almost seizure free) and 2 individuals had not reached the 12-month follow-up. Complications at 30 days included 1 case of aseptic meningitis that resolved with therapy (ATML), 2 cases of postoperative partial visual field deficits (MRgLITT) and 1 case of postoperative seizure requiring readmission (MRgLITT). There were no significant differences in neuropsychological outcomes between the two groups. The authors note that MRgLITT might be an acceptable alternative for those individuals who cannot or are not willing to undergo an open surgical intervention.</p><p>The current body of evidence is limited to case review and series, and prospective and retrospective studies. While randomized, controlled studies comparing minimally invasive procedures to the gold standard of ATL provides a high level of evidence, this type of study is not feasible for LITT in the current setting. The preponderance of evidence suggests that the efficacy of LITT is comparable to open procedures and has improved safety and tolerance outcomes (Curry, 2012; Drane, 2015; Hawasli, 2013; Lewis, 2015; McCracken, 2016; Ogasawara, 2022; Patel, 2016; Perry, 2017; Tao, 2018; Tandon, 2018b; Wang, 2021; Wilfong, 2013; Willie, 2014; Wu, 2019; Youngerman, 2018). In all of the cited studies evaluating MRgLITT, no more than 2 epileptogenic lesions were treated.</p><p><em>Radiofrequency therapies</em></p><p>SEEG-guided RF-TC, also called thermo-SEEG, involves the use of implanted SEEG electrodes to both identify the location of seizure-onset zones and to perform multiple stereotactic lesioning of the identified areas. SEEG-guided RF-TC is proposed as alternative in a select population when resective surgery is not feasible, such as when the ictal onset zone size is limited or when the zone is located in a highly functional area (Moles, 2018). Moles (2018) notes the following advantages to SEEG-guided RF-TC:</p><ol style="list-style-type:lower-roman">	<li>there is no additional bleeding risk when compared to a conventional stereotactic procedure as the same electrode is used for both SEEG and RF-TC (all bleedings reported in the literature were related to removal of SEEG electrodes, and these were not those used for RF-TC [9]),</li>	<li>it allows a very accurate targeting of the seizure-onset zone, previously delineated by intracranial recordings,</li>	<li>multiple lesions can be performed, instead of the single or double lesions usually performed in a conventional stereotactic lesioning procedure, and</li>	<li>a functional mapping, through direct electrical stimulation on SEEG electrodes, is done prior to any lesion being made, thus allowing to anticipate the possible adverse effects in detail.</li></ol><p>In a retrospective review comparing the outcomes of SEEG-guided RF-TC (n=21) and ATL (n=49) in temporal lobe epilepsy, Moles and associates (2018) reported significantly worse outcomes for the SEEG-guided RF-TC group. At 12 months, none of the SEEG-guided RF-TC group were seizure free while 75.5% of the ATL group were seizure free. Of the 21 individuals in the SEEG-guided RF-TC group, 19 individuals subsequently underwent ATL, 1 individual was waiting to undergo ATL, and the last individual was seizure-free for 2 months before being classified as a responder (at least 50% reduction in seizure frequency).</p><p>Bourdillon and associates (2017) evaluated the outcomes 162 individuals who underwent SEEG-guided RF-TC to treat drug-resistant focal epilepsy. The primary outcome was identified as seizure frequency at 2 months and 1 year following SEEG-guided RF-TC. In addition, the rate of responders, defined as individuals with at least a 50% decrease in seizure frequency compared to the 3 months immediately preceding the procedure, was the secondary outcome. At 2 months, 25% (n=41) of the individuals were seizure free and 67% (n=108) were considered responders. At 12 months, 7% (n=11) of the individuals were seizure free and 48% (n=78) of the individuals were considered responders. A total of 50 individuals underwent a second procedure within the year following the procedure, 2 of those individuals had a second SEEG-guided RF-TC. While the results of this study might suggest that SEEG-guided RF-TC has a favorable risk-benefit ratio compared to conventional surgery and other palliative treatments, the significance of these finding was limited by the prospective nature of the study and the fact this single center study was performed over a 10-year period and included modifications in practice over this time.</p><p>Radiofrequency ablation has been studied as a means of eliminating epileptogenic zones without performing a craniotomy. While early results were disappointing, later studies have reported improved outcomes over the earlier data (LaRiviere, 2016). However, these later studies are small, lower quality studies (Gu&eacute;not, 2004; Gu&eacute;not, 2011; Kr&aacute;msk&aacute;, 2017; Malikova, 2014; Wu, 2014). Additional study with long-term follow-up is needed to address questions regarding efficacy, safety and durability of outcomes compared to current standard treatments. In a critical review summarizing the literature and personal experiences with SEEG-guided RF-TC, Wu and associates (2014) note that in addition to comparing outcomes with standard treatments, more accurate devices are needed, concluding &ldquo;Technically, developing new devices for RF-TC that provide intraoperative control over lesion temperature and real-time lesion visualization would help produce ablated volumes as expected with better outcomes&rdquo;.</p><p>In 2022, Kerezoudis and colleagues conducted a systematic review and meta-analysis of RF-TC for medically refractory epilepsy. A total of 20 studies involving 360 subjects were analyzed. Among patients with at least 12 months of follow-up (n = 267, 74% of cohort), a favorable seizure outcome (Engel I/II class) was observed in 62% of cases. Hypothalamic hamartomas, periventricular gray matter heterotopias and mesial temporal epilepsy had the most successful responses. New neurological deficits developed in 10% of subjects, with 2% remaining permanently. Monopolar RF-TC, a higher number of RF-TC lesions and the presence of lesional MRI were associated with significantly higher rates of favorable seizure outcome. The authors concluded that although radiofrequency ablation is unlikely to provide seizure freedom, it may play a role in reducing frequency of debilitating seizures when surgical resection is not feasible. Randomized trials are needed to confirm the value of this intervention compared to other types of epilepsy surgery.</p><p><em>Hypothalamic hamartomas (HH)</em></p><p>HH is a rare congenital ventral hypothalamus malformation which often results in treatment-resistant epilepsy (Kerrigan, 2017). The disorder affects an estimated 1 in every 200,000 individuals. HH can present in several ways although intractable gelastic seizures are a common symptom (Kameyama, 2016). In addition to the gelastic seizures, approximately half of the affected individuals also have epileptic encephalopathy, which is exhibited as cognitive impairment and behavioral disorders. Gelastic seizures typically do not respond to pharmacotherapy, treatment options include microscopic surgery, endoscopic disconnection, stereotactic radiofrequency thermocoagulation (SRT), laser interstitial thermal therapy, and Gamma Knife surgery (Tandon, 2018a). The location of HH lesions, near of the midline of the skull base, make the lesions difficult to reach with microsurgical approaches and too invasive to provide total resection (Kameyama, 2016). The success rate of microscopic surgery has been reported as 5-60% with higher rates of morbidity and mortality (Tandon, 2018a). In addition to treating gelastic seizures, both laser and radiofrequency procedures have been associated with an improvement in epileptic encephalopathy symptoms (Sonoda, 2017).</p><p>Sonoda and associates (2017) evaluated cognitive function outcomes in 88 individuals who underwent SRT as a treatment of drug-resistant gelastic seizures (GS). A total of 87 individuals underwent post-operative follow-up for an average of 3.3 years. At the final hospital visit, 85.2% (75/87) had achieved GS remission. For those individuals in gelastic seizure remission there was a significant post-operative improvement in full-scale intelligence quotient (FSIQ) compared to preoperative scores (preoperative 72.8 &plusmn; 25.1 versus postoperative at the last visit 81.2 &plusmn; 26.7; p&lt;0.001; paired t-test). Individuals who did not achieve GS remission did not achieve a significant improvement in FSIQ scores (preoperative 68.8 &plusmn; 23.3 versus postoperative at the last visit 71.1 &plusmn; 24.1: p=0.36; paired t-test).</p><p>Kameyama and colleagues (2016) reported on the outcomes of 100 consecutive pediatric (n=70) and adult (n=30) individuals with intractable gelastic seizures who underwent MRI-guided stereotactic radiofrequency thermocoagulation (SRT). In addition to gelastic seizures, 90 of the individuals had other types of seizures including complex partial, secondarily generalized tonic-clonic, tonic, atonic, myoclonic and epileptic. All individuals had SRT as the sole treatment for hypothalamic hamartomas, although 32 individuals underwent multiple (up to 4) SRT procedures for residual disease. Individuals were followed-up between 1 and 17 years. A reported 86% of the individuals achieved freedom from gelastic seizures and 78.9% of the individuals with concurrent non-gelastic seizures also achieved seizure freedom.</p><p>Several other studies, including case series, retrospective reviews, and systematic reviews that reported on the outcomes of either stereotactic laser ablation or stereotactic radiofrequency thermocoagulation used to treat HH lesions have been published. Both laser and SRT trials have reported outcomes superior to microscopic surgery with limited morbidity (Curry, 2018; Iranmehr, 2022; Kameyama, 2016; Kondajji, 2021; Southwell, 2018; Tandon, 2018a; Wei, 2018).</p><p><em>Other minimally invasive therapies</em></p><p>To date, there is a paucity of studies regarding other minimally invasive treatments of epilepsy. Chkhenkeli and colleagues (2013) reported on the results of 21 individuals who underwent stereotactic cryosurgery to treat intractable bitemporal epilepsy. However, there have been no additional published regarding the use of cryosurgery for the treatment of epilepsy.</p><table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Definitions</strong></td>		</tr>	</tbody></table><p>Anterior temporal lobectomy (ATL): Surgical resection of the of mesial-basal temporal lobe structures. A limitation of ATL is that access to these structures requires resection of the temporal neocortex which affects cognitive and neuropsychological abilities.</p><p>Epilepsy: A disease of the brain when any of the following conditions occur:</p><ul>	<li>At least two unprovoked (or reflex) seizures occurring &gt; 24 h apart</li>	<li>One unprovoked, or reflex, seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years</li>	<li>Diagnosis of an epilepsy syndrome</li></ul><p>Medically intractable epilepsy: The failure of at least two separate drug regimens to control seizure activity; also known as drug resistant epilepsy.</p><p>Selective amygdalohippocampectomy (SAH): Surgical resection of mesial-basal temporal lobe structures which does not involve neocortical resection.</p><table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>References</strong></td>		</tr>	</tbody></table><p><strong>Peer Reviewed Publications:</strong></p><ol>	<li>Al Sufiani F, Ang LC. Neuropathology of temporal lobe epilepsy. Epilepsy Res Treat. 2012:624519.</li>	<li>Barot N, Batra K, Zhang J, et al. Surgical outcomes between temporal, extratemporal epilepsies and hypothalamic hamartoma: systematic review and meta-analysis of MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy. J Neurol Neurosurg Psychiatry. 2021 Jul 28:jnnp-2021-326185.</li>	<li>Bourdillon P, Isnard J, Catenoix H, et al. Stereo electroencephalography-guided radiofrequency thermocoagulation (SEEG-guided RF-TC) in drug-resistant focal epilepsy: results from a 10-year experience. Epilepsia. 2017; 58(1):85-93.</li>	<li>Buckley R, Estronza-Ojeda S, Ojemann JG. Laser Ablation in Pediatric Epilepsy. Neurosurg Clin N Am. 2016; 27(1):69-78.</li>	<li>Chang EF, Englot DJ, Vadera S. Minimally invasive surgical approaches for temporal lobe epilepsy. Epilepsy Behav. 2015; 47:24-33.</li>	<li>Chen JS, Lamoureux AA, Shlobin NA, et al. Magnetic resonance-guided laser interstitial thermal therapy for drug-resistant epilepsy: a systematic review and individual participant data meta-analysis. Epilepsia. 2023; 64(8):1957-1974.</li>	<li>Chkhenkeli SA, &Scaron;ramka M, Rakviashvili TN, et al. Bitemporal intractable epilepsy: could it be surgically treatable? Stereotact Funct Neurosurg. 2013; 91(2):104-112.</li>	<li>Curry DJ, Gowda A, McNichols RJ, Wilfong AA. MR-guided stereotactic laser ablation of epileptogenic foci in children. Epilepsy Behav. 2012; 24(4):408-414.</li>	<li>Curry DJ, Raskin J, Ali I, Wilfong AA. MR-guided laser ablation for the treatment of hypothalamic hamartomas. Epilepsy Res. 2018; 142:131-134.</li>	<li>Donos C, Breier J, Friedman E, et al. Laser ablation for mesial temporal lobe epilepsy: surgical and cognitive outcomes with and without mesial temporal sclerosis. Epilepsia. 2018; 59:1421-1432.</li>	<li>Dorfer C, Rydenhag B, Baltuch G, et al. How technology is driving the landscape of epilepsy surgery. Epilepsia. 2020; 61(5):841-855.</li>	<li>Drane DL, Loring DW, Voets NL, et al. Better object recognition and naming outcome with MRI-guided stereotactic laser amygdalohippocampotomy for temporal lobe epilepsy. Epilepsia. 2015; 56(1):101-113.</li>	<li>Engel J Jr. What can we do for people with drug-resistant epilepsy? The 2016 Wartenberg Lecture. Neurology. 2016; 87(23):2483-2489.</li>	<li>Grewal SS, Zimmerman RS, Worrell G, et al. Laser ablation for mesial temporal epilepsy: a multi-site, single institutional series. J Neurosurg. 2018:1-8.</li>	<li>Gross RE, Stern MA, Willie JT, et al. Stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Ann Neurol. 2018; 83(3):575-587.</li>	<li>Gross RE, Willie JT, Drane DL. The role of stereotactic laser amygdalohippocampotomy in mesial temporal lobe epilepsy. Neurosurg Clin N Am. 2016; 27(1):37-50.</li>	<li>Gu&eacute;not M, Isnard J, Catenoix H, Maugui&egrave;re F, Sindou M. SEEG-guided RF-thermocoagulation of epileptic foci: a therapeutic alternative for drug-resistant non-operable partial epilepsies. Adv Tech Stand Neurosurg. 2011; 36:61-78.</li>	<li>Gu&eacute;not M, Isnard J, Ryvlin P, et al. SEEG-guided RF thermocoagulation of epileptic foci: feasibility, safety, and preliminary results. Epilepsia. 2004; 45(11):1368-1374.</li>	<li>Hawasli AH, Bagade S, Shimony JS, et al. Magnetic resonance imaging-guided focused laser interstitial thermal therapy for intracranial lesions: single-institution series. Neurosurgery. 2013; 73(6):1007-1017.</li>	<li>Iranmehr A, Dabbagh Ohadi MA, et al. Minimally invasive procedures for hypothalamic hamartoma-related epilepsy: a systematic review and meta-analysis. Neurosurg Focus. 2022; 53(4):E8.</li>	<li>Kameyama S, Shirozu H, Masuda H, et al. MRI-guided stereotactic radiofrequency thermocoagulation for 100 hypothalamic hamartomas. Neurosurg. 2016; 124:1503-1512.</li>	<li>Kang JY, Wu C, Tracy J, et al. Laser interstitial thermal therapy for medically intractable mesial temporal lobe epilepsy. Epilepsia. 2016; 57(2):325-334.</li>	<li>Kerezoudis P, Parisi V, Marsh WR, et al. Surgical outcomes of laser interstitial thermal therapy for temporal lobe epilepsy: systematic review and meta-analysis. World Neurosurg. 2020; 143:527-536.e3.</li>	<li>Kerezoudis P, Tsayem IN, Lundstrom BN, Van Gompel JJ. Systematic review and patient-level meta-analysis of radiofrequency ablation for medically refractory epilepsy: Implications for clinical practice and research. Seizure. 2022; 102:113-119.</li>	<li>Kerrigan JF, Parsons A, Tsang C, et al. Hypothalamic hamartoma: Neuropathology and epileptogenesis. Epilepsia. 2017; 58 Suppl 2:22-31.</li>	<li>Kohlhase K, Z&ouml;llner JP, Tandon N, et al. Comparison of minimally invasive and traditional surgical approaches for refractory mesial temporal lobe epilepsy: a systematic review and meta-analysis of outcomes. Epilepsia. 2021; 62(4):831-845.</li>	<li>Kondajji AM, Evans A, Lum M, et al. A systematic review of stereotactic radiofrequency ablation for hypothalamic hamartomas. J Neurol Sci. 2021; 424:117428.</li>	<li>Kr&aacute;msk&aacute; L, VojtÄ›ch Z, Lukavsk&yacute; J, et al. Five-year neuropsychological outcome after stereotactic radiofrequency amygdalohippocampectomy for mesial temporal lobe epilepsy: longitudinal study. Stereotact Funct Neurosurg. 2017; 95:149-157.</li>	<li>Lagman C, Chung LK, Pelargos PE, et al. Laser neurosurgery: a systematic analysis of magnetic resonance-guided laser interstitial thermal therapies. J Clin Neurosci. 2017; 36:20-26.</li>	<li>LaRiviere MJ, Gross RE. Stereotactic laser ablation for medically intractable epilepsy: the next generation of minimally invasive epilepsy surgery. Front Surg. 2016; 3:64.</li>	<li>Lewis EC, Weil AG, Duchowny M, et al. MR-guided laser interstitial thermal therapy for pediatric drug-resistant lesional epilepsy. Epilepsia. 2015; 56(10):1590-1598.</li>	<li>Malikova H, Kramska L, Vojtech Z, et al. Different surgical approaches for mesial temporal epilepsy: resection extent, seizure, and neuropsychological outcomes. Stereotact Funct Neurosurg. 2014; 92(6):372-380.</li>	<li>McCracken DJ, Willie JT, Fernald B, et al. Magnetic resonance thermometry-guided stereotactic laser ablation of cavernous malformations in drug-resistant epilepsy: imaging and clinical results. Oper Neurosurg (Hagerstown). 2016; 12(1):39-48.</li>	<li>Moles A, Gu&eacute;not M, Rheims S, et al. SEEG-guided radiofrequency coagulation (SEEG-guided RF-TC) versus anterior temporal lobectomy (ATL) in temporal lobe epilepsy. J Neurol. 2018; 265(9):1998-2004.</li>	<li>Ogasawara C, Watanabe G, Young K, et al. Laser interstitial thermal therapy for cerebral cavernous malformations: a systematic review of indications, safety, and outcomes. World Neurosurg. 2022; 166:279-287.</li>	<li>Patel P, Patel NV, Danish SF. Intracranial MR-guided laser-induced thermal therapy: single-center experience with the Visualase thermal therapy system. J Neurosurg. 2016; 125(4):853-860.</li>	<li>Perry MS, Donahue DJ, Malik SI, et al. Magnetic resonance imaging-guided laser interstitial thermal therapy as treatment for intractable insular epilepsy in children. J Neurosurg Pediatr. 2017; 20(6):575-582.</li>	<li>Shukla ND, Ho AL, Pendharkar AV, et al. Laser interstitial thermal therapy for the treatment of epilepsy: evidence to date. Neuropsychiatr Dis Treat. 2017; 13:2469-2475.</li>	<li>Sonoda M, Masuda H, Shirozu H, et al. Predictors of cognitive function in patients with hypothalamic hamartoma following stereotactic radiofrequency thermocoagulation surgery. Epilepsia. 2017; 58(9):1556-1565.</li>	<li>Southwell DG, Birk HS, Larson PS, et al. Laser ablative therapy of sessile hypothalamic hamartomas in children using interventional MRI: report of 5 cases. J Neurosurg Pediatr. 2018; 21:460-465.</li>	<li>Spencer D, Burchiel K. Selective amygdalohippocampectomy. Epilepsy Res Treat. 2012; 2012:382095.</li>	<li>Tandon V, Chandra PS, Doddamani RS, et al. Stereotactic radiofrequency thermocoagulation of hypothalamic hamartoma using robotic guidance (ROSA) coregistered with O-arm guidance-preliminary technical note. World Neurosurg. 2018a; 112:267-274</li>	<li>Tandon V, Lang M, Chandra PS, et al. Is edema a matter of concern after laser ablation of epileptogenic focus? World Neurosurg. 2018b; 113:366-372.e3.</li>	<li>Tao JX, Wu S, Lacy M, et al. Stereotactic EEG-guided laser interstitial thermal therapy for mesial temporal lobe epilepsy. J Neurol Neurosurg Psychiatry. 2018; 89(5):542-548.</li>	<li>Wang R, Beg U, Padmanaban V, et al. A systematic review of minimally invasive procedures for mesial temporal lobe epilepsy: too minimal, too fast? Neurosurgery. 2021; 89(2):164-176.</li>	<li>Wang Y, Xu J, Liu T, et al. Magnetic resonance-guided laser interstitial thermal therapy versus stereoelectroencephalography-guided radiofrequency thermocoagulation for drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsy Res. 2020; 166:106397.</li>	<li>Waseem H, Osborn KE, Schoenberg MR, et al. Laser ablation therapy: an alternative treatment for medically resistant mesial temporal lobe epilepsy after age 50. Epilepsy Behav. 2015; 51:152-157.</li>	<li>Waseem H, Vivas AC, Vale FL. MRI-guided laser interstitial thermal therapy for treatment of medically refractory non-lesional mesial temporal lobe epilepsy: outcomes, complications, and current limitations: a review. J Clin Neurosci. 2017; 38:1-7.</li>	<li>Wei PH, An Y, Fan XT, et al. Stereoelectroencephalography-guided radiofrequency thermocoagulation for hypothalamic hamartomas: preliminary evidence. World Neurosurg. 2018; 114:e1073-e1078.</li>	<li>Wilfong AA, Curry DJ. Hypothalamic hamartomas: optimal approach to clinical evaluation and diagnosis. Epilepsia. 2013; 54 Suppl 9:109-114.</li>	<li>Willie JT, Laxpati NG, Drane DL, et al. Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. Neurosurgery. 2014; 74(6):569-585.</li>	<li>Wu C, Jermakowicz WJ, Chakravorti S, et al. Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients. Epilepsia. 2019; 60(6):1171-1183.</li>	<li>Wu Z, Zhao Q, Tian Z, et al. Efficacy and safety of a new robot-assisted stereotactic system for radiofrequency thermocoagulation in patients with temporal lobe epilepsy. Exp Ther Med. 2014; 7(6):1728- 1732.</li>	<li>Xue F, Chen T, Sun H. Postoperative Outcomes of Magnetic Resonance Imaging (MRI)-Guided Laser Interstitial Thermal Therapy (LITT) in the Treatment of Drug-Resistant Epilepsy: A Meta-Analysis. Med Sci Monit. 2018; 24:9292-9299.</li>	<li>Youngerman BE, Oh JY, Anbarasan D, et al; Columbia Comprehensive Epilepsy Center Co-Authors. Laser ablation is effective for temporal lobe epilepsy with and without mesial temporal sclerosis if hippocampal seizure onsets are localized by stereoelectroencephalography. Epilepsia. 2018; 59(3):595-606.</li>	<li>Youngerman BE, Save AV, McKhann GM. Magnetic resonance imaging-guided laser interstitial thermal therapy for epilepsy: systematic review of technique, indications, and outcomes. Neurosurgery. 2020; 86(4):E366-E382.</li></ol><p><strong>Government Agency, Medical Society, and Other Authoritative Publications:</strong></p><ol>	<li>Centers for Disease Control and Prevention (CDC). Epilepsy Data and Statistics. Updated March 29, 2023. Available at: <a href="https://www.cdc.gov/epilepsy/data/index.html" style="color:blue; text-decoration:underline">https://www.cdc.gov/epilepsy/data/index.html</a>. Accessed on September 15, 2023.</li>	<li>Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014; 55(4):475-82.</li>	<li>Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51(6):1069-1077.</li>	<li>Laser Interstitial Thermal Therapy for Treating Laser Interstitial Thermal Therapy for Treating Intracranial Lesions and Epilepsy. A Health Technology Assessment and Policy Analysis. January 27, 2016. Available at: <a href="https://obrieniph.ucalgary.ca/sites/default/files/Nav%20Bar/Groups/HTA/litt-jan-27th-2016-references-fixed.pdf" style="color:blue; text-decoration:underline">https://obrieniph.ucalgary.ca/sites/default/files/Nav%20Bar/Groups/HTA/litt-jan-27th-2016-references-fixed.pdf</a>. Accessed on September 15, 2023.</li>	<li>U.S. Food &amp; Drug Administration:	<ul style="list-style-type:disc">		<li>NeuroBlate<sup>&reg;</sup> System (Monteris Medical; Plymouth, MN). 510(K) Number: K173305. November 17, 2017. Available at: <a href="https://www.accessdata.fda.gov/cdrh_docs/pdf17/K173305.pdf" style="color:blue; text-decoration:underline">https://www.accessdata.fda.gov/cdrh_docs/pdf17/K173305.pdf</a>. Accessed on September 15, 2023.</li>		<li>Visualase<sup>&reg;</sup> Thermal Therapy System (Medtronic; Minneapolis, MN). 510(K) Number: K053087. March 1, 2006. Available at: <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K053087" style="color:blue; text-decoration:underline">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K053087</a>. Accessed on September 15, 2023.</li>	</ul>	</li>	<li>Wu C, Schwalb JM, Rosenow JM et al. The American Society for Stereotactic and Functional Neurosurgery position statement on laser interstitial thermal therapy for the treatment of drug-resistant epilepsy. Neurosurgery. 2022; 90:155-160.</li></ol><table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Websites for Additional Information</strong></td>		</tr>	</tbody></table><ol>	<li>National Institute of Health. National Institute of Neurological Disorders and Stroke. Epilepsy Information Page. Last updated August 15, 2023. Available at: <a href="https://www.ninds.nih.gov/disorders/all-disorders/epilepsy-information-page" style="color:blue; text-decoration:underline">https://www.ninds.nih.gov/disorders/all-disorders/epilepsy-information-page</a>. Accessed on September 15, 2023.</li>	<li>National Organization for Rare Disorders (NORD). Hypothalamic Hamartoma. Last updated August 16, 2017. Available at: <a href="https://rarediseases.org/rare-diseases/hypothalamic-hamartoma/" style="color:blue; text-decoration:underline">https://rarediseases.org/rare-diseases/hypothalamic-hamartoma/</a>. Accessed on September 15, 2023.</li>	<li>The Epilepsy Foundation. Understanding Epilepsy. What is Epilepsy? Available at: <a href="https://www.epilepsy.com/what-is-epilepsy" style="color:blue; text-decoration:underline">https://www.epilepsy.com/what-is-epilepsy</a><u style="text-decoration:underline">. </u>Accessed on September 15, 2023.</li></ol><table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>Index</strong></td>		</tr>	</tbody></table><p><strong>The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.</strong></p><table border="1" bordercolor="#000000" cellpadding="0" cellspacing="0" style="width:100%">	<tbody>		<tr>			<td class="head_stripe" width="100%"><strong>History</strong></td>		</tr>	</tbody></table><table cellspacing="0" class="Table" style="border-collapse:collapse; margin-left:7px; width:682px">	<tbody>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:90px">			<p><strong>Status</strong></p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:101px">			<p><strong>Date</strong></p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:491px">			<p><strong>Action</strong></p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:90px">			<p>Revised</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:101px">			<p>11/09/2023</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:491px">			<p>Medical Policy &amp; Technology Assessment Committee (MPTAC) review. Reformatted MN criteria in Clinical Indications section. Updated Discussion/General Information, References, and Websites for Additional Information sections.</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:90px">			<p>Reviewed</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:101px">			<p>11/10/2022</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:491px">			<p>MPTAC review. Updated Discussion/General Information, References, and Websites sections. Updated Coding section, added ICD-10-PCS code 00503Z3.</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:90px">			<p>Reviewed</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:101px">			<p>11/11/2021</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:491px">			<p>MPTAC review. Updated Discussion/General Information, References, and Websites sections.</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:90px">			<p>Reviewed</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:101px">			<p>11/05/2020</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:491px">			<p>MPTAC review. Updated Discussion, References and Websites sections. Reformatted Coding section.</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:90px">			<p>Reviewed</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:101px">			<p>11/07/2019</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:491px">			<p>MPTAC review. Updated Discussion, References and Websites sections.</p>			</td>		</tr>		<tr>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:90px">			<p>New</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:101px">			<p>11/08/2018</p>			</td>			<td style="padding:0in 7px 0in 7px; vertical-align:top; width:491px">			<p>MPTAC review. Initial document development.</p>			</td>		</tr>	</tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><hr /><p>Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy &amp; Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member&#39;s card.</p><p>Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan&rsquo;s or line of business&rsquo;s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.</p><p>No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.</p><p>&copy; CPT Only - American Medical Association</p><noscript><img src="https://www.anthem.com/akam/13/pixel_705d9972?a=dD02ZDg4OGQ2YzM5NmU3NGQxMjQzMmRjOTNjOGJlMzhmZWQxZmI0Zjc0JmpzPW9mZg==" style="visibility: hidden; position: absolute; left: -999px; top: -999px;" /></noscript><script type="text/javascript"  src="/iOP-/eY9D/A/kZ/IVzY-qg/OuYDVXwhtJ/aioOJQUXBw/JwpDFiM/2Xh4"></script></body>			</html>